Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is eyeing at high single-digit growth in its consolidated topline this fiscal (FY24) on the back of robust performance from all its business verticals. The Mumbai-based company had reported a consolidated revenue of Rs 43,278 crore in 2022-23.

The company also expects expansion of its global specialty business to continue in the ongoing financial year. The company's R&D spending is expected to be 7-8 per cent of sales in FY24 with an increasing share of spending expected on clinical trials for specialty products.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.